Literature DB >> 10230749

Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors.

N Ketterer1, D Espinouse, M Chomarat, C Dumontet, I Moullet, C Rieux, E M Neidhardt-Berard, F Bouafia, B Coiffier, G Salles.   

Abstract

PURPOSE: We sought to describe the infections that occur after large-dose chemotherapy, which was followed by autologous peripheral blood progenitor cell transplantation, and to determine their risk factors. PATIENTS AND METHODS: We retrospectively analyzed the occurrence and the characteristics of infections in 277 consecutive patients who received intensive chemotherapy for non-Hodgkin's lymphoma (n = 207), Hodgkin's disease (n = 27), or multiple myeloma (n = 43) in a single institution. Conditioning regimens included total body irradiation in 47% of the cases. Infections occurring within the 30 days after transplant were defined as early infections, whereas infections after that time in patients who had achieved a neutrophil count greater than 1.0 x 10(9)/L (1,000 per microL) were considered as late infections.
RESULTS: Within the first 30 days, 172 patients had unexplained fever (62%); infections were documented in 83 patients (30%), most commonly bacteremia (57 patients). Late infections occurred in 64 (26%) of 244 evaluable patients and consisted mainly of varicella zoster virus infections (n = 36) and pneumonia (n = 16). Administration of total body irradiation [odds ratio (OR) = 2.50; 95% confidence interval (CI) 1.4 to 4.5; P = 0.002) and previous use of fludarabine (OR 2.5; CI 1.2 to 5.2; P = 0.02) and a diagnosis of myeloma (OR 2.6; CI 1.2 to 5.6; P = 0.04) were significantly associated with late infections.
CONCLUSIONS: This study confirms that infectious toxicity after peripheral blood progenitor cell transplantation is usually moderate, although bacteremia remains a serious problem. Late infections are encountered in about 25% of patients and are more common in those with myeloma, or those who received total body irradiation or fludarabine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230749     DOI: 10.1016/s0002-9343(98)00409-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

Review 1.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

2.  The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients.

Authors:  Cybele Lara R Abad; Brian Lahr; John C O'Horo; Prakhar Vijayvargiya; Randall C Walker; William J Hogan; Aaron J Tande
Journal:  Int J Hematol       Date:  2019-11-11       Impact factor: 2.490

3.  Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.

Authors:  Michael Boeckh; Hyung W Kim; Mary E D Flowers; Joel D Meyers; Raleigh A Bowden
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

4.  Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.

Authors:  Caron A Jacobson; Amin T Turki; Sean M McDonough; Kristen E Stevenson; Haesook T Kim; Grace Kao; Maria I Herrera; Carol G Reynolds; Edwin P Alyea; Vincent T Ho; John Koreth; Philippe Armand; Yi-Bin Chen; Karen Ballen; Robert J Soiffer; Joseph H Antin; Corey S Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-26       Impact factor: 5.742

Review 5.  Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.

Authors:  Jessica Caro; Marc Braunstein; Louis Williams; Benedetto Bruno; David Kaminetzky; Ariel Siegel; Beatrice Razzo; Serge Alfandari; Gareth J Morgan; Faith E Davies; Eileen M Boyle
Journal:  Leukemia       Date:  2022-02-02       Impact factor: 12.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.